ClinicalTrials.gg
CompletedNCT01453296Updated Jan 13, 2017Results posted

Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects

A Phase 2 interventional study of GW642444 and Placebo in Asthma, sponsored by GlaxoSmithKline. Completed at 5 sites in United States. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-01-13.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
5 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing vilanterol in Asthma — none open to participants now, 2 under way, 2 of them phase 3. vilanterol · Asthma.

Enrollment
19th of 30
28 · median 69
Started
2010
with 9 others
Phase 2
6 of 30
none open now
Registered
13th of 30
by date
Lead sponsor
27 of 30
GlaxoSmithKline

Among the 30 studies testing vilanterol in Asthma, this one is the 19th largest by enrollment, is one of 10 that started in 2010, is one of 6 in phase 2, and was the 13th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 30 studies testing vilanterol in Asthma is open now. The open studies under Asthma, anywhere →

About vilanterol

vilanterol: first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing vilanterol in Asthma as a file.
02

Study summary

This study will investigate the effect of dosing paedeatric asthmatic subjects with GW642444, an orally inhaled long-acting agonist of the β2-adrenoceptor.

Read the detailed description

This study will investigate the effect of dosing with 25 μg GW642444, an orally inhaled long-acting agonist of the β2-adrenoceptor, in asthmatic subjects aged 5 to 11. GW642444 is currently under development as the long-acting beta-agonist component of a combination product containing an inhaled corticosteroid and a longacting beta-agonist.

Subjects will receive a single dose via a novel dry powder inhaler, then 7 days once-daily repeat dosing following a washout period. The study will be a randomized two-way crossover, with a placebo control. Approximately 26 subjects will be recruited to this study, with the aim that 20 will complete the study. Safety, tolerability, pharmacokinetics and glucose and potassium levels will be investigated.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Tolerability
  • Safety
  • Pharmacokinetics
  • GW642444
04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and pre-menarchial female subjects aged 5-11 years on the last planned treatment day are eligible for this study. Pre-menarchial females are defined as any female who has yet to begin menses and is considered Tanner Stage 2 or less.
  • Diagnosis of asthma at least 6 months prior to screening.
  • Patients must be controlled on their existing asthma treatment at Screening as defined by a Childhood Asthma Control Test score of >19 and PEF (Peak Expiratory Flow) >75 % predicted.
  • Subjects must be taking a stable regimen of fluticasone propionate (≤200 μg (micrograms) twice daily or equivalent) and short acting beta-agonist inhaler on an as-need basis for at least 4 weeks prior to screening.
  • Apart from asthma, eczema and rhinitis, subjects should be healthy and suffer from no other significant medical conditions.
  • Subjects must weigh at least 15 kg (kilograms).
  • Subjects must demonstrate ability to accept and effectively use the GW642444 device using the demonstration kits provided to the site.
  • The subject and parent or guardian are able to understand and comply with protocol requirements, instructions, and protocol-stated restrictions. The parent or guardian must have the ability to read, write and record diary information collected throughout the study. The parent or guardian must also have the ability to manage study drug administration and PEF assessments.
  • At least one parent or guardian has signed and dated the written prior to admission to the study. This will be accompanied by informed assent from the subject.

Exclusion criteria

Exclusion Criteria:

  • Subjects currently receiving (or have received within 4 weeks of screening) any of the following asthma therapies: theophyllines, long-acting inhaled beta-agonists, oral beta-agonist.
  • Subjects who have changed their asthma medication within 4 weeks of screening.
  • Clinical visual evidence of oral candidiasis at screening.
  • Any abnormality identified on the screening medical assessment
  • Any medical condition or circumstance making the subject unsuitable for participation in the study (e.g. history of life-threatening asthma)
  • Asthma exacerbation requiring systemic (oral, intramuscular, intravenous) or Emergency Room attendance within 3 months or asthma exacerbation requiring hospitalization within 6 months prior to the screening visit.
  • Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract which is not resolved within 4 weeks of the screening visit.
  • Any adverse reaction including immediate or delayed to any betaagonist therapy.
  • Known or suspected sensitivity to the constituents of the novel dry powder inhaler (i.e., lactose or magnesium stearate), for example, history of severe milk protein allergy.
  • The parent or guardian has history of psychiatric disease, intellectual deficiency, substance abuse, or other condition (e.g., inability to read, comprehend or write) which will limit the validity of consent to participate in this study.
  • A subject will not be eligible for this study if he/she is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator.
  • Children who are wards of the state or government.
  • Evidence of clinically significant abnormality in the 12-lead (electrocardiogram) at Screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Active comparator
    COHORT 1 (RANDOMISATION AB or BA)

    8-11 years old; Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence. Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home). Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods.

    Drug: GW642444 · Drug: Placebo

  • Active comparator
    COHORT 2 (RANDOMISATION AB or BA)

    5-7 years old. Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence. Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home). Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods.

    Drug: GW642444 · Drug: Placebo

Interventions

  • GW642444 25 μg; Novel dry powder inhaler

  • DrugPlacebo

    Matching placebo; Novel dry powder inhaler

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General AE/SAE module for a complete list of AEs and SAEs.

    Time frame: From the start of study medication until Week 11 (Visit 8)/Early Withdrawal

  2. Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelets, and white blood cell (WBC) count at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  3. Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of hemoglobin and MCHC at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  4. Reticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of reticulocytes and RBCs at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  5. Hematocrit Value at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of hematocrit at Day 14 of the respective treatment period. Hematocrit is a measure of the percentage of the volume of the whole blood that is composed of red blood cells, as determined by separation of red blood cells from the plasma (usually by centrifugation). Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  6. Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of MCV at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  7. Mean Corpuscle Hemoglobin (MCH) Value at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of MCH at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  8. Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  9. Albumin and Total Protein Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of albumin and total protein at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  10. Calcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of calcium, chloride, carbon dioxide content/bicarbonate (CO2/BI), glucose, potassium, sodium, and urea/BUN at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  11. Total Bilirubin, Direct Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period

    Blood samples were collected for the measurement of total bilirubin, direct bilirubin, creatinine, and uric acid at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  12. Peak Expiratory Flow on Day 1, Day 8, and Day 14 of the Respective Treatment Period

    Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF is calculated as the maximum of three readings taken at each timepoint for each participant. Baseline is defined as the pre-dose measurement at Day 1 for the respective period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).

    Time frame: Day 1, Day 8, and Day 14 of the respective treatment period (up to Study Day 49)

  13. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1, Day 8, and Day 14 of the Respective Treatment Period

    SBP and DBP were measured at Day 1, Day 8, and Day 14 of the respective treatment period. PD=post-dose. Baseline is defined as the pre-dose measurement at Day 1 for the respective period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).

    Time frame: Day 1, Day 8, and Day 14 of the respective treatment period (up to Study Day 49)

  14. Maximum Heart Rate at Day 1 and Day 14 of the Respective Treatment Period

    Heart rate (HR) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)

  15. Weighted Mean Heart Rate at Day 1 and Day 14 of the Respective Treatment Period

    Heart rate (HR) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative times were used for these observations. For 0-8 hr parameters, treatment, period, participant Baseline, and period Baseline were fitted as fixed effects, and participant was fitted as a random effect. For 0-2 hr parameters, treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)

  16. Maximum QTcF at Day 1 and Day 14 of the Respective Treatment Period

    The electrocardiographic (ECG) parameter QT duration corrected using Fridericia's formula (QTcF) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. For 0-8 hr parameters, treatment, period, participant Baseline, and period Baseline were fitted as fixed effects, and participant was fitted as a random effect. For 0-2 hr parameters, treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)

  17. Weighted Mean QTcF at Day 1 and Day 14 of the Respective Treatment Period

    The electrocardiographic (ECG) parameter QT duration corrected using Fridericia's formula (QTcF) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative times were used for these observations. For 0-8 hr parameters, treatment, period, participant Baseline, and period Baseline were fitted as fixed effects, and participant was fitted as a random effect. For 0-2 hr parameters, treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)

Secondary outcomes

  1. AUC(0-t) and AUC(0-8) on Day 14 of the Respective Treatment Period

    Area under the concentration-time (AUC) curve from time zero (pre-dose) to the last time AUC(0-t) and from time zero to 8 hours AUC(0-8) of quantifiable concentration of VI on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period. Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the Pharmacokinetic Population.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  2. Cmax on Day 14 of the Respective Treatment Period

    Cmax is defined as the maximum observed concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  3. Tmax, t1/2, and t at Day 14 of the Respective Treatment Period

    tmax is defined as the time to reach the observed maximum concentration, t1/2 is defined as the time required to reduce the plasma concentration to one half its initial value, and t is defined as the time of the last observed quantifiable concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  4. Blood Glucose and Potassium on Day 14 of the Respective Treatment Period

    Blood glucose and potassium values were measured on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period. . Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative times were used for these observations. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg. Treatment and period were fitted as fixed effects and participant was fitted as a random effect.

    Time frame: Day 14 of the respective treatment period (up to Study Day 49)

  5. Average Oropharyngeal Cross-sectional Area on Day 1 and Day 14 of the Respective Treatment Period

    During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for the study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Pharyngometry data were recorded for each day (Day 1 and Day 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)

  6. Distance of Assessment on Day 1 and Day 14 of the Respective Treatment Period

    During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Distance of assessment is defined as the distance (length measured in centimeters \[cm\]) estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)

  7. Oropharyngeal Volume on Day 1 and Day 14 of the Respective Treatment Period

    During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Oropharyngeal volume is defined as the volume (centimeters cubed \[cm\^3\]) of the mouth and throat estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)

  8. Average Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Day 1 and Day 14 of the Respective Treatment Period

    During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Average flow rate is defined as the average inspiratory flow rate (Liters \[L\]/min) across the inhalation profile when inhaling across the resistance of the inhaler. PIFR is defined as the Peak Inspiratory Flow Rate (L/min) of the inhalation profile when inhaling across the resistance of the inhaler.The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the average flow rate and PIFR were determined. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)

  9. Inhalation Time on Day 1 and Day 14 of the Respective Treatment Period

    During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhalation time is defined as the duration of the inhalation(s) when inhaling across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalation time was determined. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)

  10. Inhaled Volume on Day 1 and Day 14 of the Respective Treatment Period

    During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhaled volume is defined as the volume of air (Liters) inhaled during the inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalaled volume was determined. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)

  11. Peak Pressure Drop on Day 1 and Day 14 of the Respective Treatment Period

    During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Peak pressure drop is defined as the maximum pressure drop (kilopascal \[kPa\]) achieved during inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was calculated for each day (Days 1 and 14 of the respective treatment period), and used for subsequent modeling and prediction of dose emission attributes. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)

  12. Total Emitted Dose (TED) on Day 1 and Day 14 of the Respective Treatment Period

    The total emitted dose (TED) is defined as the mass (micrograms) of the nominal dose that passes beyond the throat. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted total emitted dose.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)

  13. Ex-throat Dose (ETD) and ETD <2 Microns on Day 1 and Day 14 of the Respective Treatment Period

    The ex-throat dose (ETD) and the "nominal ETD" is the mass (micrograms) of active investigational material that passes beyond the throat, nominal being the mean.The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted ETD and ETD \<2 microns.

    Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 49)

07

Results

Posted Aug 19, 2013

Participant flow

Participants were enrolled into one of two cohorts based upon age; the younger cohort was enrolled after a review of the safety/pharmacokinetic data of at least six participants from the older cohort. Each participant was assigned to treatment randomly; assignment was not to be influenced by whether participants were in Cohort 1 or Cohort 2.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneSequence 1: VI 25 µg Followed by PlaceboSequence 2: Placebo Followed by VI 25 µg
Started1414
Completed1313
Not completed11
Withdrew: Adverse event01
Withdrew: Met protocol-defined stopping criteria10
Washout Period
Participant flow — Washout Period
MilestoneSequence 1: VI 25 µg Followed by PlaceboSequence 2: Placebo Followed by VI 25 µg
Started1313
Completed1313
Not completed00
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneSequence 1: VI 25 µg Followed by PlaceboSequence 2: Placebo Followed by VI 25 µg
Started1313
Completed1113
Not completed20
Withdrew: Adverse event10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryNumber of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General AE/SAE module for a complete list of AEs and SAEs.

Time frame:
From the start of study medication until Week 11 (Visit 8)/Early Withdrawal
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period
ParticipantsPlaceboVI 25 µg
Any AE69
Any SAE00
PrimaryBasophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelets, and white blood cell (WBC) count at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · 10^9 cells per liter (GI/L)
Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period
10^9 cells per liter (GI/L)PlaceboVI 25 µg
Basophils, n=24, 250.021 ± 0.01450.034 ± 0.0185
Eosinophils, n=24, 250.276 ± 0.30020.348 ± 0.3458
Lymphocytes, n=24, 252.404 ± 0.86522.419 ± 0.8729
Monocytes, n=24, 250.268 ± 0.13100.376 ± 0.1419
Total neutrophils, n=24, 253.354 ± 1.30543.127 ± 0.9625
Platelets, n=23, 25280.7 ± 54.11279.4 ± 54.71
WBCs, n=24, 256.32 ± 1.8086.30 ± 1.640
PrimaryHemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of hemoglobin and MCHC at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · Grams per liter (g/L)
Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period
Grams per liter (g/L)PlaceboVI 25 µg
Hemoglobin, n=24, 25133.0 ± 11.30130.7 ± 11.22
MCHC, n=24, 25337.1 ± 5.50338.3 ± 11.60
PrimaryReticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of reticulocytes and RBCs at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · 10^12 cells per liter (TI/L)
Reticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period
10^12 cells per liter (TI/L)PlaceboVI 25 µg
Reticulocytes, n=24, 250.05010 ± 0.0206960.05275 ± 0.024571
RBCs, n=24, 254.60 ± 0.3744.47 ± 0.339
PrimaryHematocrit Value at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of hematocrit at Day 14 of the respective treatment period. Hematocrit is a measure of the percentage of the volume of the whole blood that is composed of red blood cells, as determined by separation of red blood cells from the plasma (usually by centrifugation). Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · proportion of 1
Hematocrit Value at Day 14 of the Respective Treatment Period
proportion of 1PlaceboVI 25 µg
Hematocrit Value at Day 14 of the Respective Treatment Period0.3948 ± 0.034300.3863 ± 0.02617
PrimaryMean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of MCV at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · 10^15 femtoliters (fL) per cell
Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period
10^15 femtoliters (fL) per cellPlaceboVI 25 µg
Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period86.0 ± 4.0886.6 ± 3.59
PrimaryMean Corpuscle Hemoglobin (MCH) Value at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of MCH at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · 10^12 picograms (pg) per cell
Mean Corpuscle Hemoglobin (MCH) Value at Day 14 of the Respective Treatment Period
10^12 picograms (pg) per cellPlaceboVI 25 µg
Mean Corpuscle Hemoglobin (MCH) Value at Day 14 of the Respective Treatment Period28.97 ± 1.33729.29 ± 1.464
PrimaryAlanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · International units per liter (IU/L)
Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period
International units per liter (IU/L)PlaceboVI 25 µg
ALT, n=22, 2513.9 ± 4.2113.5 ± 3.56
ALP, n=22, 25260.5 ± 109.65273.4 ± 103.51
AST, n=22, 2427.7 ± 6.1125.5 ± 4.52
GGT, n=22, 2514.1 ± 4.1213.6 ± 3.51
PrimaryAlbumin and Total Protein Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of albumin and total protein at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · Grams per liter
Albumin and Total Protein Values at Day 14 of the Respective Treatment Period
Grams per literPlaceboVI 25 µg
Albumin, n=22, 2542.8 ± 2.9543.2 ± 1.96
Total protein, n=22, 2567.9 ± 4.8268.6 ± 3.16
PrimaryCalcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of calcium, chloride, carbon dioxide content/bicarbonate (CO2/BI), glucose, potassium, sodium, and urea/BUN at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · Millimoles per liter (mmol/L)
Calcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period
Millimoles per liter (mmol/L)PlaceboVI 25 µg
Calcium, n=22, 242.327 ± 0.13572.359 ± 0.0666
Chloride, n=22, 25105.5 ± 3.90105.1 ± 2.01
CO2 content/bicarbonate, n=22, 2417.6 ± 2.3018.1 ± 1.98
Glucose, n=22, 254.95 ± 0.5105.04 ± 0.513
Potassium, n=22, 244.30 ± 0.4084.33 ± 0.242
Sodium, n=22, 25137.7 ± 2.43137.8 ± 2.12
Urea/BUN, n=22, 254.91 ± 1.3684.48 ± 1.150
PrimaryTotal Bilirubin, Direct Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period

Blood samples were collected for the measurement of total bilirubin, direct bilirubin, creatinine, and uric acid at Day 14 of the respective treatment period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · Micromoles per liter (µmol/L)
Total Bilirubin, Direct Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period
Micromoles per liter (µmol/L)PlaceboVI 25 µg
Total bilirubin, n=22, 256.2 ± 2.225.8 ± 1.99
Direct bilirubin, n=22, 251.7 ± 0.941.2 ± 1.00
Creatinine, n=22, 2539.45 ± 7.65339.35 ± 6.731
Uric acid, n=22, 25241.4 ± 69.51245.6 ± 47.27
PrimaryPeak Expiratory Flow on Day 1, Day 8, and Day 14 of the Respective Treatment Period

Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF is calculated as the maximum of three readings taken at each timepoint for each participant. Baseline is defined as the pre-dose measurement at Day 1 for the respective period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).

Time frame:
Day 1, Day 8, and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · liters/minute
Peak Expiratory Flow on Day 1, Day 8, and Day 14 of the Respective Treatment Period
liters/minutePlaceboVI 25 µg
Day 1, Baseline, n=26, 28230.6 ± 72.55233.0 ± 68.55
Day 1, 20 minutes post-dose, n=26, 28237.5 ± 69.65245.6 ± 73.47
Day 8, Pre-dose, n=26, 28232.1 ± 64.76228.8 ± 64.42
Day 8, 20 minutes post-dose, n=25, 28233.8 ± 220.0240.7 ± 65.66
Day 14, Pre-dose, n=24, 26240.3 ± 75.90239.0 ± 72.02
Day 14, 20 minutes post-dose, n=24, 26243.3 ± 75.18248.1 ± 76.20
PrimarySystolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1, Day 8, and Day 14 of the Respective Treatment Period

SBP and DBP were measured at Day 1, Day 8, and Day 14 of the respective treatment period. PD=post-dose. Baseline is defined as the pre-dose measurement at Day 1 for the respective period. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).

Time frame:
Day 1, Day 8, and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · Millimeters of mercury (mmHg)
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1, Day 8, and Day 14 of the Respective Treatment Period
Millimeters of mercury (mmHg)PlaceboVI 25 µg
Day 1 SBP, Baseline, n=26, 28101.8 ± 6.59102.9 ± 9.21
Day 1 SBP, 10 minutes PD, n=26, 28100.7 ± 7.59102.4 ± 7.69
Day 1 SBP, 30 minutes PD, n=26, 28100.9 ± 9.35103.5 ± 6.89
Day 1 SBP, 45 minutes PD, n=26, 28100.9 ± 7.41103.5 ± 7.05
Day 1 SBP, 74 minutes PD, n=26, 28102.7 ± 7.95104.4 ± 6.81
Day 1 SBP, 2 hours PD, n=26, 28103.3 ± 8.16104.8 ± 7.82
Day 8 SBP, Pre-dose, n=25, 2899.6 ± 6.92103.7 ± 8.64
Day 8 SBP, 30 minutes PD, n=25, 28101.7 ± 7.29102.9 ± 7.31
Day 8 SBP, 1 hour PD, n=25, 28101.8 ± 8.38103.6 ± 7.17
Day 14 SBP, Pre-dose, n=24, 26101.5 ± 9.18103.9 ± 6.15
Day 14 SBP, 10 minutes PD, n=24, 26101.3 ± 9.98103.7 ± 6.70
Day 14 SBP, 30 minutes PD, n=24, 26103.9 ± 8.72102.9 ± 8.91
Day 14 SBP, 45 minutes PD, n=24, 26103.6 ± 7.95103.4 ± 7.03
Day 14 SBP, 75 minues PD, n=24, 26104.9 ± 8.33103.9 ± 6.36
Day 14 SBP, 4 hours PD, n=24, 26102.2 ± 7.80106.0 ± 5.20
Day 14 SBP, 2 hours PD, n=24, 26103.0 ± 6.68102.9 ± 6.42
Day 14 SBP, 8 hours PD, n=24, 26104.7 ± 8.92104.7 ± 7.76
Day 1 DBP, Baseline, n=26, 2862.0 ± 5.1262.1 ± 6.38
Day 1 DBP, 10 minutes PD, n=26, 2862.4 ± 7.1663.5 ± 4.08
Day 1 DBP, 30 minutes PD, n=26, 2862.4 ± 6.5562.6 ± 4.29
Day 1 DBP, 45 minutes PD, n=26, 2863.0 ± 7.9363.3 ± 5.99
Day 1 DBP, 75 minutes PD, n=26, 2863.3 ± 5.7464.4 ± 7.91
Day 1 DBP, 2 hours PD, n=26, 2863.0 ± 4.8163.4 ± 5.49
Day 8 DBP, Pre-dose, n=25, 2863.7 ± 8.1762.8 ± 5.58
Day 8 DBP, 30 minutes PD, n=25, 2862.3 ± 9.1962.4 ± 7.26
Day 8 DBP, 1 hour PD, n=25, 2863.2 ± 6.6862.2 ± 7.90
Day 14 DBP, Pre-dose, n=24, 2660.8 ± 5.7063.8 ± 8.14
Day 14 DBP, 10 minutes PD, n=24, 2660.9 ± 6.5562.7 ± 7.07
Day 14 DBP, 30 minutes PD, n=24, 2662.8 ± 3.8363.7 ± 7.88
Day 14 DBP, 45 minutes PD, n=24, 2661.9 ± 4.0564.5 ± 4.68
Day 14 DBP, 75 minutes PD, n=23, 2663.0 ± 5.1263.6 ± 6.34
Day 14 DBP, 2 hours PD, n=23, 2664.1 ± 7.3363.3 ± 5.50
Day 14 DBP, 4 hours PD, n=23, 2662.3 ± 8.5663.9 ± 6.59
Day 14 DBP, 8 hours PD, n=23, 2663.2 ± 4.7863.3 ± 7.29
PrimaryMaximum Heart Rate at Day 1 and Day 14 of the Respective Treatment Period

Heart rate (HR) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Least squares mean · Beats per minute
Maximum Heart Rate at Day 1 and Day 14 of the Respective Treatment Period
Beats per minutePlaceboVI 25 µg
Day 1 maximum HR (0-2 hr), n=26, 2883.6 ± 1.4486.1 ± 1.40
Day 14 maximum HR (0-2 hr), n=24, 2684.3 ± 1.3885.0 ± 1.35
Day 14 maximum HR (0-8 hr), n=24, 2688.1 ± 1.4588.6 ± 1.41
Statistical analysis
  • Placebo vs VI 25 µg · Mean difference (final values): 2.5 · 95% CI -0.8 to 5.7Day 1 maximum HR (0-2 hr). The estimated value represents the treatment difference: VI 25 µg minus placebo.
  • Placebo vs VI 25 µg · Mean difference (final values): 0.6 · 95% CI -2.4 to 3.7Day 14 maximum HR (0-2 hr). The estimated value represents the treatment difference: VI 25 µg minus placebo.
  • Placebo vs VI 25 µg · Mean difference (final values): 0.5 · 95% CI -2.6 to 3.6Day 14 maximum HR (0-8 hr). The estimated value represents the treatment difference: VI 25 µg minus placebo.
PrimaryWeighted Mean Heart Rate at Day 1 and Day 14 of the Respective Treatment Period

Heart rate (HR) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative times were used for these observations. For 0-8 hr parameters, treatment, period, participant Baseline, and period Baseline were fitted as fixed effects, and participant was fitted as a random effect. For 0-2 hr parameters, treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Least squares mean · Beats per minute
Weighted Mean Heart Rate at Day 1 and Day 14 of the Respective Treatment Period
Beats per minutePlaceboVI 25 µg
Day 1 weighted HR (0-2 hr), n=26, 2876.39 ± 1.31179.20 ± 1.285
Day 14 weighted mean HR (0-2 hr), n=23, 2676.11 ± 1.30977.67 ± 1.264
Day 14 weighted mean HR (0-8 hr), n=23, 2680.54 ± 1.45880.65 ± 1.404
Statistical analysis
  • Placebo vs VI 25 µg · Mean difference (final values): 2.5 · 95% CI -0.8 to 5.7Day 1 weighted HR (0-2 hr). The estimated value represents the treatment difference: VI 25 µg minus placebo.
  • Placebo vs VI 25 µg · Mean difference (final values): 0.6 · 95% CI -2.4 to 3.7Day 14 weighted HR (0-2 hr). The estimated value represents the treatment difference: VI 25 µg minus placebo.
  • Placebo vs VI 25 µg · Mean difference (final values): 0.5 · 95% CI -2.6 to 3.6Day 14 weighted HR (0-8 hr). The estimated value represents the treatment difference: VI 25 µg minus placebo.
PrimaryMaximum QTcF at Day 1 and Day 14 of the Respective Treatment Period

The electrocardiographic (ECG) parameter QT duration corrected using Fridericia's formula (QTcF) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. For 0-8 hr parameters, treatment, period, participant Baseline, and period Baseline were fitted as fixed effects, and participant was fitted as a random effect. For 0-2 hr parameters, treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Least squares mean · milliseconds
Maximum QTcF at Day 1 and Day 14 of the Respective Treatment Period
millisecondsPlaceboVI 25 µg
Day 1 maximum QTcF (0-2 hr), n=26, 28405.6 ± 2.29406.6 ± 2.22
Day 14 maximum QTcF (0-2 hr), n=24, 26406.1 ± 2.06407.7 ± 2.00
Day 14 maximum QTcF (0-8 hr), n=24, 26407.8 ± 1.87409.2 ± 1.82
Statistical analysis
  • Placebo vs VI 25 µg · Mean difference (final values): 1.0 · 95% CI -4.5 to 6.6Day 1 maximum QTcF (0-2 hr). The estimated value represents the treatment difference: VI 25 µg minus placebo.
  • Placebo vs VI 25 µg · Mean difference (final values): 1.6 · 95% CI -3.2 to 6.3Day 14 maximum QTcF (0-2 hr). The estimated value represents the treatment difference: VI 25 µg minus placebo.
  • Placebo vs VI 25 µg · Mean difference (final values): 1.3 · 95% CI -3.0 to 5.7Day 14 maximum QTcF (0-8 hr). The estimated value represents the treatment difference: VI 25 µg minus placebo.
SecondaryAUC(0-t) and AUC(0-8) on Day 14 of the Respective Treatment Period

Area under the concentration-time (AUC) curve from time zero (pre-dose) to the last time AUC(0-t) and from time zero to 8 hours AUC(0-8) of quantifiable concentration of VI on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period. Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the Pharmacokinetic Population.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Geometric mean · picograms*hour per milliliter (pg*hr/mL)
AUC(0-t) and AUC(0-8) on Day 14 of the Respective Treatment Period
picograms*hour per milliliter (pg*hr/mL)PlaceboVI 25 µg
AUC(0-t), n=25—132.8 (96.0 to 183.8)
AUC(0-8), n=19—181.7 (145.0 to 227.7)
SecondaryCmax on Day 14 of the Respective Treatment Period

Cmax is defined as the maximum observed concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Geometric mean · picograms per milliliter (pg/mL)
Cmax on Day 14 of the Respective Treatment Period
picograms per milliliter (pg/mL)PlaceboVI 25 µg
Cmax on Day 14 of the Respective Treatment Period—97.44 (64.83 to 146.45)
SecondaryTmax, t1/2, and t at Day 14 of the Respective Treatment Period

tmax is defined as the time to reach the observed maximum concentration, t1/2 is defined as the time required to reduce the plasma concentration to one half its initial value, and t is defined as the time of the last observed quantifiable concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Median · hours
Tmax, t1/2, and t at Day 14 of the Respective Treatment Period
hoursPlaceboVI 25 µg
tmax, n=23—0.20 (0.00 to 1.00)
t1/2, n=14—3.131 (1.06 to 6.32)
t, n=23—6.00 (1.00 to 8.13)
SecondaryBlood Glucose and Potassium on Day 14 of the Respective Treatment Period

Blood glucose and potassium values were measured on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, 4, 6, and 8 hours post-dose for participants who were \>=20 kilograms and pre-dose; 10 min and 30 min post-dose; and 1, 2, and 4 hours post-dose for participants who were \<=20 kilograms on Day 14 of the respective treatment period. . Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative times were used for these observations. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg. Treatment and period were fitted as fixed effects and participant was fitted as a random effect.

Time frame:
Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Least squares mean · Millimoles per liter (mmol/L)
Blood Glucose and Potassium on Day 14 of the Respective Treatment Period
Millimoles per liter (mmol/L)PlaceboVI 25 µg
Maximum Glucose (0-2 hr), n=24, 265.55 ± 0.1845.57 ± 0.182
Maximum Glucose (0-8 hr), n=24, 266.22 ± 0.1876.03 ± 0.183
Weighted Mean Glucose (0-2 hr), n=21, 255.02 ± 0.1145.06 ± 0.109
Weighted Mean Glucose (0-8 hr), n=19, 245.26 ± 0.1085.21 ± 0.100
Minimum Potassium (0-2 hr), n=23, 264.05 ± 0.0404.00 ± 0.038
Minimum Potassium (0-8 hr), n=24, 263.89 ± 0.0603.87 ± 0.059
Weighted Mean Potassium (0-2 hr), n=19, 224.21 ± 0.0494.23 ± 0.046
Weighted Mean Potassium (0-8 hr), n=17, 224.05 ± 0.0524.11 ± 0.049
SecondaryAverage Oropharyngeal Cross-sectional Area on Day 1 and Day 14 of the Respective Treatment Period

During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for the study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Pharyngometry data were recorded for each day (Day 1 and Day 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · centimeters squared (cm^2)
Average Oropharyngeal Cross-sectional Area on Day 1 and Day 14 of the Respective Treatment Period
centimeters squared (cm^2)PlaceboVI 25 µg
Day 1, n=15, 135.65 ± 1.8344.42 ± 2.310
Day 14, n=14, 155.47 ± 1.6615.16 ± 2.139
SecondaryDistance of Assessment on Day 1 and Day 14 of the Respective Treatment Period

During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Distance of assessment is defined as the distance (length measured in centimeters \[cm\]) estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · centimeters (cm)
Distance of Assessment on Day 1 and Day 14 of the Respective Treatment Period
centimeters (cm)PlaceboVI 25 µg
Day 1, n=15, 1318.40 ± 1.50218.26 ± 1.824
Day 14, n=14, 1518.46 ± 1.39518.41 ± 1.276
SecondaryOropharyngeal Volume on Day 1 and Day 14 of the Respective Treatment Period

During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Oropharyngeal volume is defined as the volume (centimeters cubed \[cm\^3\]) of the mouth and throat estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · cm^3
Oropharyngeal Volume on Day 1 and Day 14 of the Respective Treatment Period
cm^3PlaceboVI 25 µg
Day 1, n=15, 13102.33 ± 32.45178.60 ± 39.296
Day 14, n=14, 15102.26 ± 36.32293.35 ± 37.190
SecondaryAverage Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Day 1 and Day 14 of the Respective Treatment Period

During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Average flow rate is defined as the average inspiratory flow rate (Liters \[L\]/min) across the inhalation profile when inhaling across the resistance of the inhaler. PIFR is defined as the Peak Inspiratory Flow Rate (L/min) of the inhalation profile when inhaling across the resistance of the inhaler.The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the average flow rate and PIFR were determined. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · Liters per minute (L/min)
Average Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Day 1 and Day 14 of the Respective Treatment Period
Liters per minute (L/min)PlaceboVI 25 µg
Day 1, Average flow rate, n=23, 2538.84 ± 9.44042.23 ± 10.952
Day 14, Average flow rate, n=23, 2540.45 ± 10.53842.08 ± 10.191
Day 1, PIFR, n=23, 2558.27 ± 14.25861.41 ± 16.513
Day 14, PIFR, n=23, 2560.93 ± 14.90161.79 ± 15.348
SecondaryInhalation Time on Day 1 and Day 14 of the Respective Treatment Period

During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhalation time is defined as the duration of the inhalation(s) when inhaling across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalation time was determined. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · Seconds (sec)
Inhalation Time on Day 1 and Day 14 of the Respective Treatment Period
Seconds (sec)PlaceboVI 25 µg
Day 1, n=23, 251.45 ± 0.6041.36 ± 0.551
Day 14, n=23, 251.35 ± 0.5281.34 ± 0.476
SecondaryInhaled Volume on Day 1 and Day 14 of the Respective Treatment Period

During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhaled volume is defined as the volume of air (Liters) inhaled during the inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalaled volume was determined. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · Liters
Inhaled Volume on Day 1 and Day 14 of the Respective Treatment Period
LitersPlaceboVI 25 µg
Day 1, n=23, 250.93 ± 0.4330.92 ± 0.343
Day 14, n=23, 250.90 ± 0.4260.95 ± 0.417
SecondaryPeak Pressure Drop on Day 1 and Day 14 of the Respective Treatment Period

During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Peak pressure drop is defined as the maximum pressure drop (kilopascal \[kPa\]) achieved during inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was calculated for each day (Days 1 and 14 of the respective treatment period), and used for subsequent modeling and prediction of dose emission attributes. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · Kilopascal (kpa)
Peak Pressure Drop on Day 1 and Day 14 of the Respective Treatment Period
Kilopascal (kpa)PlaceboVI 25 µg
Day 1, n=23, 252.97 ± 1.2753.33 ± 1.632
Day 14, n=23, 253.23 ± 1.4793.33 ± 1.350
SecondaryTotal Emitted Dose (TED) on Day 1 and Day 14 of the Respective Treatment Period

The total emitted dose (TED) is defined as the mass (micrograms) of the nominal dose that passes beyond the throat. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted total emitted dose.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · micrograms
Total Emitted Dose (TED) on Day 1 and Day 14 of the Respective Treatment Period
microgramsPlaceboVI 25 µg
Nominal TED—20.28 ± 0.177
Minimum TED—20.24 ± 0.188
Maximum TED—20.31 ± 0.173
SecondaryEx-throat Dose (ETD) and ETD <2 Microns on Day 1 and Day 14 of the Respective Treatment Period

The ex-throat dose (ETD) and the "nominal ETD" is the mass (micrograms) of active investigational material that passes beyond the throat, nominal being the mean.The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted ETD and ETD \<2 microns.

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Mean · micrograms
Ex-throat Dose (ETD) and ETD <2 Microns on Day 1 and Day 14 of the Respective Treatment Period
microgramsPlaceboVI 25 µg
Nominal ETD—9.00 ± 0.697
Minimum ETD—8.94 ± 0.652
Maximum ETD—9.06 ± 0.747
ETD <2 microns—4.19 ± 1.079
Minimum ETD <2 microns—4.10 ± 1.011
Maximum ETD <2 microns—4.29 ± 1.157
PrimaryWeighted Mean QTcF at Day 1 and Day 14 of the Respective Treatment Period

The electrocardiographic (ECG) parameter QT duration corrected using Fridericia's formula (QTcF) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative times were used for these observations. For 0-8 hr parameters, treatment, period, participant Baseline, and period Baseline were fitted as fixed effects, and participant was fitted as a random effect. For 0-2 hr parameters, treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect. Subject 2308 received VI 25 µg in both treatment periods, and contributed twice to the summary of VI 25 µg (n=28).

Time frame:
Day 1 and Day 14 of the respective treatment period (up to Study Day 49)
Reported as:
Least squares mean · milliseconds
Weighted Mean QTcF at Day 1 and Day 14 of the Respective Treatment Period
millisecondsPlaceboVI 25 µg
Day 1 weighted mean QTcF (0-2 hr), n=26, 28394.21 ± 2.007396.22 ± 1.960
Day 14 weighted mean QTcF (0-2 hr), n=23, 26395.09 ± 2.122398.03 ± 2.024
Day 14 weighted mean QTcF (0-8 hr), n=23, 26393.43 ± 1.867396.62 ± 1.793
Statistical analysis
  • Placebo vs VI 25 µg · Mean difference (final values): 2.01 · 95% CI -2.59 to 6.61Day 1 weighted QTcF (0-2 hr). The estimated value represents the treatment difference: VI 25 µg minus placebo.
  • Placebo vs VI 25 µg · Mean difference (final values): 2.94 · 95% CI -1.93 to 7.81Day 14 weighted QTcF (0-2 hr). The estimated value represents the treatment difference: VI 25 µg minus placebo.
  • Placebo vs VI 25 µg · Mean difference (final values): 3.19 · 95% CI -0.70 to 7.08Day 14 weighted QTcF (0-8 hr). The estimated value represents the treatment difference: VI 25 µg minus placebo.

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/26 (0%)6/26 (23.1%)
VI 25 µg—0/27 (0%)9/27 (33.3%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlaceboVI 25 µg
Upper respiratory tract infectionInfections and infestations0/263/27
HeadacheNervous system disorders2/262/27
PyrexiaGeneral disorders0/262/27
SinusitisInfections and infestations1/260/27
Urinary tract infectionInfections and infestations1/260/27
Sinus bradycardiaCardiac disorders1/260/27
DyspepsiaGastrointestinal disorders1/260/27
Conversion disorderPsychiatric disorders1/260/27
DisorientationPsychiatric disorders1/260/27
Otitis mediaInfections and infestations0/261/27

Baseline characteristics

Age, Continuous
Age, Continuous(Years)VI 25 µg/Placebo or Placebo/VI 25 µg
Mean8.0 ± 1.90
Gender
Gender(Participants)VI 25 µg/Placebo or Placebo/VI 25 µg
Female10
Male18
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VI 25 µg/Placebo or Placebo/VI 25 µg
African American/African Heritage5
White - White/Caucasian/European Heritage22
Mixed Race1
08

Study locations

5 sites
  • GSK Investigational Site
    Cypress, California 90630, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Denver, Colorado 80206, United States
  • GSK Investigational Site
    Normal, Illinois 61761, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 2 years 4 months after primary completion. A results delay was requested in Jul 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2011
First posted
Oct 17, 2011
Start
Aug 2010
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Results delay requested
Jul 26, 2012
Results first posted
Aug 19, 2013
Last update
Jan 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01453296
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 17, 2011
Start date
Aug 2010
Primary completion
Apr 2011
Completion
Apr 2011
Results posted
Aug 19, 2013
Last update
Jan 13, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vilanterol

Start the discussion